ALKS: Alkermes plc 2021-10-25 07:00:00 Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa in Combination With Pembrolizumab for the Treatment of Platinum-Resistant Ovarian Cancer
Today's action (10/27) demonstrates the risks of making projections in close proximity to the reporting of earnings.
From what I can see, the earnings report was great, but revenues fell a few percent short of expectations. It could take some weeks for the price to recover to where it was yesterday. In the meantime, there are other good stocks to grab while ALKS is in recovery mode. NemAlfa is still a drug in clinical trial and nothing is guaranteed.
From what I can see, the earnings report was great, but revenues fell a few percent short of expectations. It could take some weeks for the price to recover to where it was yesterday. In the meantime, there are other good stocks to grab while ALKS is in recovery mode. NemAlfa is still a drug in clinical trial and nothing is guaranteed.